Basic View | Expanded View
Showing 61-69 of 69 Articles
Letters | 
Yalçin Velibey, MD; Tolga S. Guvenc, MD; Murat Ugur, MD; Ozge Guzelburc, MD; and Mehmet Eren, MD
Position Papers | 
Hilary Daniel, BS, for the Health and Public Policy Committee of the American College of Physicians
This American College of Physicians position paper, initiated and written by its Health and Public Policy Committee and approved by the Board of Regents on 16 February 2016, reports policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States. Prescription drugs play an important part in treating and preventing disease. However, the United States often pays more for some prescription drugs than other developed countries, and the high price and increasing costs associated with prescription medication is a major concern for patients, physicians, and payers. Pharmaceutical companies have considerable flexibility in how they price drugs, and the costs that payers and patients see are dependent on how payers are able to negotiate discounts or rebates. Beyond setting list prices are issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits. These issues are linked, and comprehensive efforts will be needed to affect how drugs are priced in the United States.
Topics: prescriptions, drug, prescription drug, formulary, pharmaceutical company, american college of physicians
Ideas and Opinions | 
Shmuel Shoham, MD; Annukka A.R. Antar, MD, PhD; Paul G. Auwaerter, MD, MBA; Christine M. Durand, MD; Mark S. Sulkowski, MD; and Deborah J. Cotton, MD, MPH
Prevention of antimicrobial shortages is a fundamental aspect of keeping patients free of harm. When shortages of these drugs are coupled with the dynamics of serious infections, the results can be catastrophic. The authors discuss possible incentives, programs, and regulation that could help to combat the problem.
Topics: antimicrobials
Letters | 
Kalyan C. Mantripragada, MD, MPH; Sophia Fircanis Rizk, MD; John L. Reagan, MD; and Mark LeGolvan, MD
Letters | 
Caroline M. Lee, MD, PhD; Jason D. Lee, MD, PhD; Lisa D. Hobson-Webb, MD; Richard S. Bedlack, MD, PhD; and Joseph K. Salama, MD
This case report describes an alternative approach for treating thymoma-associated myasthenia gravis.
Ideas and Opinions | 
Evan M. Bloch, MD, MS; Matthew S. Simon, MD, MS; and Beth H. Shaz, MD
Thirty years ago, the recognition that HIV was transmitted through transfusion led to sweeping changes in the procurement, testing, and regulation of the blood supply. Transmission of pathogens, including hepatitis C virus, West Nile virus, and HIV, via transfusion has now been virtually eliminated. However, the authors argue that in 2016, new economic challenges and the emergence of global pathogens, such as Zika virus, call for new investments in blood bank infrastructure and testing technologies, as well as improved collaboration among stakeholders.
Topics: communicable diseases, emerging, safety, transfusion
Physicians increasingly practice as employees of large organizations; therefore, they may often report to managers who are not physicians. These managers may not share physicians' professional values and may believe that practices learned in business school apply to all organizations, including hospitals. This commentary discusses how clauses in the contracts that physicians sign with their employers or that their employers sign with third parties may be part of a growing class of subtle restrictions on employed physicians' professionalism and autonomy.
Topics: professionalism, employer, hospitals
Letters | 
Sean O'Loghlen, MD, BSc(Hons); Grayson J. Hall, MD; Nadil Zeiadin, MD; Laura Milne, MD; and Benedetto Mussari, MD
Clinicians usually can identify the cause of unilateral lower extremity swelling, but even experienced clinicians can be misled by rare causes of this condition. This case report describes unilateral lower extremity swelling that can be mistaken for deep venous thrombosis.
Two states, Oregon and California, now allow pharmacists to prescribe and dispense oral hormonal birth control, which some see as a step toward improved access. However, a prescription is still required in these cases. In this commentary, the Chief Executive Officer of the American Congress of Obstetricians and Gynecologists describes how pharmacist prescription simply exchanges one barrier for another and why over-the-counter availability of oral contraceptives would be a better strategy for increasing access to safe, effective birth control.
Topics: oral contraceptives, contraceptive methods, pharmacist, drugs, non-prescription
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.